“Preventive Medicine” has arrived for those at risk for HIV. New medical strategies are available to help prevent HIV from being transmitted. As futuristic as this concept seems, it is part of a preventive revolution for medical care – where an “ounce of prevention” may be worth more than a “pound of cure.”
Raphael Landovitz’s clinical research career focuses on optimizing the use of HIV antiretroviral therapy for both HIV treatment and HIV prevention. Dr. Landovitz was trained at Princeton University and Harvard Medical School. He completed post-graduate training in internal medicine at Brigham and Women’s Hospital (1996-1999) and Infectious Diseases and HIV Medicine at Brigham and Women’s Hospital and Massachusetts General Hospital (1999-2001). He works in the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the NICHD-funded Adolescent Trials Network (ATN), and serves as the Clinical Research Site leader of the UCLA CARE Center Clinical Research Site for the DAIDS-funded networks. He is the principal investigator of a multisite PrEP demonstration project in Los Angeles County, and the protocol chair of Phase 2a and Phase 2b/3 studies of long-acting injectable PrEP using GSK1265744 (cabotegravir).
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
infusion for HIV prevention; HPTN 083 compares daily oral Truvada to a long acting injectable antiretroviral (cabotegravir) for HIV prevention. Both studies will contribute critically important information to move the field of biomedical HIV prevention forward, and in the process bring new HIV prevention strategies to the most at-risk populations of Los Angeles County.
Dr. Steven Shoptaw, CHIPTS Co-Director, will be giving an invited address on March 11, 2016 in Vienna, Austria, at a meeting of the United Nations Office on Drugs and Crime. The purpose of the U.N. meeting is to develop science-based recommendations on ensuring access to antiretroviral therapies for people living with HIV/AIDS who also use drugs. This is one more example of the exciting and impactful work that is being conducted by CHIPTS investigators.
Medicine at UCLA. He is a Professor in two departments at UCLA (Family Medicine and Psychiatry and Biobehavioral Sciences) and Vice Chair of Research in Family Medicine. His research portfolio focuses on the treatment of addiction and on HIV prevention in the context of addiction, especially in the Western U.S. where stimulant use is the single strongest predictor of HIV transmission. For over 20 years, he has conducted Phase Ib and IIa randomized clinical trials of medications and behavioral interventions for stimulant dependent individuals. He recently completed a Phase Ib interaction safety study of ibudilast at relevant doses of methamphetamine and is a Co-Investigator on a Phase IIa randomized controlled trial of ibudilast as an outpatient treatment for methamphetamine dependence, 50% of whom are HIV-positive. He is a member of the DAIDS-funded, HIV Prevention Trials Network (HPTN) Executive Committee, and site Principal Investigator for HPTN-073, a feasibility study of Pre-Exposure Prophylaxis (Truvada) in Black men who have sex with men, 
a group with 7% incidence in Los Angeles and high rates of stimulant and alcohol use. He is also a Co-PI on a 5-year cooperative agreement (U01 DA036267) to establish a cohort of minority men who have sex with men to investigate interactions between non-injection use of methamphetamine, cocaine, opiates and binge drinking and transmission and progression of HIV.